Literature DB >> 10869284

Gastrin inhibits cholangiocyte growth in bile duct-ligated rats by interaction with cholecystokinin-B/Gastrin receptors via D-myo-inositol 1,4,5-triphosphate-, Ca(2+)-, and protein kinase C alpha-dependent mechanisms.

S Glaser1, A Benedetti, L Marucci, D Alvaro, L Baiocchi, N Kanno, A Caligiuri, J L Phinizy, U Chowdury, E Papa, G LeSage, G Alpini.   

Abstract

We studied the role of gastrin in regulating cholangiocyte proliferation induced by bile duct ligation (BDL). In purified cholangiocytes, we evaluated (1) for the presence of cholecystokinin-B (CCK-B)/gastrin receptors, (2) the effect of gastrin on D-myo-Inositol 1,4,5-triphosphate (IP(3)) levels, and (3) the effect of gastrin on DNA synthesis and adenosine 3', 5'-monophosphate (cAMP) levels in the absence or presence of CCK-A (L-364,718) and CCK-B/gastrin (L-365,260) receptor inhibitors, 1, 2-bis(2-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid tetrakis(acetxymethyl ester) (BAPTA/AM; an intracellular Ca(2+) chelator), and 2 protein kinase C (PKC) inhibitors, 1-(5-Isoquinolinylsulfonyl)-2-methylpiperazine (H7) and staurosporin. To evaluate if gastrin effects on cholangiocyte proliferation are mediated by the isoform PKCalpha, we evaluated (1) for the presence of PKCalpha in cholangiocytes and (2) the effect of gastrin on the PKCalpha protein expression in a triton-soluble (containing cytoplasm + membrane) and a triton-insoluble (containing cytoskeleton) fraction. To evaluate the effects of gastrin in vivo, immediately following BDL, gastrin or bovine serum albumin (BSA) was infused by minipumps for 7 days to rats and we measured cholangiocyte growth and cAMP levels. We found CCK-B/gastrin receptors on cholangiocytes. Gastrin increased IP(3) levels. Gastrin inhibited DNA synthesis and cAMP synthesis in cholangiocytes. Gastrin effects on cholangiocyte functions were blocked by L-365,260, BAPTA/AM, H7, and staurosporin but not by L-364,718. Gastrin induced translocation of PKCalpha from cholangiocyte cytoskeleton to membrane. In vivo, gastrin decreased cholangiocyte growth and cAMP synthesis compared with controls. We concluded that gastrin inhibits cholangiocyte growth in BDL rats by interacting with CCK-B/gastrin receptors through a signal transduction pathway involving IP(3), Ca(2+), and PKCalpha.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869284     DOI: 10.1053/jhep.2000.8265

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  47 in total

1.  Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion.

Authors:  Sharon DeMorrow; Paolo Onori; Julie Venter; Pietro Invernizzi; Gabriel Frampton; Mellanie White; Antonio Franchitto; Shelley Kopriva; Francesca Bernuzzi; Heather Francis; Monique Coufal; Shannon Glaser; Giammarco Fava; Fanyin Meng; Domenico Alvaro; Guido Carpino; Eugenio Gaudio; Gianfranco Alpini
Journal:  Am J Physiol Cell Physiol       Date:  2011-01-26       Impact factor: 4.249

2.  Histamine stimulates the proliferation of small and large cholangiocytes by activation of both IP3/Ca2+ and cAMP-dependent signaling mechanisms.

Authors:  Heather L Francis; Sharon Demorrow; Antonio Franchitto; Julie K Venter; Romina A Mancinelli; Mellanie A White; Fanyin Meng; Yoshiyuki Ueno; Guido Carpino; Anastasia Renzi; Kimberly K Baker; Hannah E Shine; Taylor C Francis; Eugenio Gaudio; Gianfranco D Alpini; Paolo Onori
Journal:  Lab Invest       Date:  2011-11-07       Impact factor: 5.662

Review 3.  Physiology of cholangiocytes.

Authors:  James H Tabibian; Anatoliy I Masyuk; Tetyana V Masyuk; Steven P O'Hara; Nicholas F LaRusso
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

4.  The Neuropeptide Galanin Is Up-Regulated during Cholestasis and Contributes to Cholangiocyte Proliferation.

Authors:  Matthew McMillin; Gabriel Frampton; Stephanie Grant; Sharon DeMorrow
Journal:  Am J Pathol       Date:  2017-02-11       Impact factor: 4.307

Review 5.  Regulation of biliary proliferation by neuroendocrine factors: implications for the pathogenesis of cholestatic liver diseases.

Authors:  Md Kamruzzaman Munshi; Sally Priester; Eugenio Gaudio; Fuquan Yang; Gianfranco Alpini; Romina Mancinelli; Candace Wise; Fanyn Meng; Antonio Franchitto; Paolo Onori; Shannon S Glaser
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 6.  Cholangiocyte proliferation and liver fibrosis.

Authors:  Shannon S Glaser; Eugenio Gaudio; Tim Miller; Domenico Alvaro; Gianfranco Alpini
Journal:  Expert Rev Mol Med       Date:  2009-02-25       Impact factor: 5.600

7.  GABA induces the differentiation of small into large cholangiocytes by activation of Ca(2+) /CaMK I-dependent adenylyl cyclase 8.

Authors:  Romina Mancinelli; Antonio Franchitto; Shannon Glaser; Fanyin Meng; Paolo Onori; Sharon Demorrow; Heather Francis; Julie Venter; Guido Carpino; Kimberley Baker; Yuyan Han; Yoshiyuki Ueno; Eugenio Gaudio; Gianfranco Alpini
Journal:  Hepatology       Date:  2013-05-14       Impact factor: 17.425

8.  Loss of inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis.

Authors:  Kazunori Shibao; Keiji Hirata; Marie E Robert; Michael H Nathanson
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

9.  Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression.

Authors:  Giammarco Fava; Sharon Demorrow; Eugenio Gaudio; Antonio Franchitto; Paolo Onori; Guido Carpino; Shannon Glaser; Heather Francis; Monique Coufal; Luca Marucci; Domenico Alvaro; Marco Marzioni; Trenton Horst; Romina Mancinelli; Antonio Benedetti; Gianfranco Alpini
Journal:  Liver Int       Date:  2009-03-09       Impact factor: 5.828

10.  Chronic nicotine exposure stimulates biliary growth and fibrosis in normal rats.

Authors:  Kendal Jensen; Syeda Afroze; Yoshiyuki Ueno; Kinan Rahal; Amber Frenzel; Melanie Sterling; Micheleine Guerrier; Damir Nizamutdinov; David E Dostal; Fanyin Meng; Shannon S Glaser
Journal:  Dig Liver Dis       Date:  2013-04-13       Impact factor: 4.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.